The announcement of Dolly's birth took the world by storm, mainly because what was thought impossible has become possible. Optimism that new approaches in agriculture and medicine abound, as much as fear and imagination leading to Frankenstein-like scenarios. Scientifically, cloning refers to replicating an animal with the same nuclear genetic material; whilst it may refer to embryos as the source material, the current storm refers to differentiated ("somatic") cells. Cloning technology is useful in the following areas: agriculture, to produce animals of superior or specific qualities; endangered animals, to increase genetic diversity through widening the gene pool; understanding fundamental questions in developmental embryology, through the use of laboratory animals; and in human therapy, to produce cells and possibly tissues for repair and regeneration. In the first 2 instances, it is reproductive cloning. In the last instance, it is therapeutic cloning, as no individuals are "produced". Human reproductive cloning is not allowed by all governments that have deliberated on it, and therapeutic cloning is allowed by some under certain circumstances. As therapeutic cloning has great potential in cures of many diseases, it should be allowed but with safeguards to prevent abuse and reproductive cloning in the human.
The objective was to evaluate the effect of the interval between ovarian hyperstimulation and laparoscopic ovum pick-up (LOPU) on quality and developmental competence of goat oocytes before and after in vitro maturation (IVM) and intracytoplasmic sperm injection (ICSI). Estrus was synchronized with an intravaginal insert containing 0.3g progesterone (CIDR) for 10d, combined with a luteolytic treatment of 125 microg cloprostenol 36 h prior to CIDR removal. Ovaries were hyperstimulated with 70 mg FSH and 500 IU hCG given im 36, 60, or 72 h prior to LOPU (n=15, 16, and 7 does, respectively). For these groups, oocyte retrieval rates (mean+/-S.E.M.) were 24.7+/-2.9, 54.5+/-4.7, and 82.8+/-4.6% (P<0.001), and the proportions of cumulus-oocyte complexes (COC) with more than five layers of cumulus cells were 29.7+/-8.3, 37.6+/-6.9, and 37.3+/-7.0% (P<0.001). The proportion of IVM oocytes was highest at 72 h (82.1+/-2.8%; P<0.05), with no significant difference between 36 and 60 h (57.3+/-8.9% and 69.0+/-8.4%). Cleavage rates of ICSI embryos were 4.2+/-4.2, 70.9+/-8.4, and 78.9+/-8.2% with LOPU 36, 60, and 72 h post FSH/hCG (P<0.01), with a lower proportion of Grade-A embryos (P<0.05) following LOPU at 36 h compared to 60 and 72 h (29.7+/-8.3%, 37.6+/-6.9%, and 37.3+/-7.0%). In summary, a prolonged interval from FSH/hCG to LOPU improved oocyte retrieval rate and oocyte quality. Therefore, under the present conditions, LOPU 60 or 72 h after FSH/hCG optimized yields of good-quality oocytes for IVM and embryo production in goats.
Atypical fertilisation patterns such as 2.1 pronuclei (2.1PN), defined by two normally sized pronuclei and an additional smaller pronucleus, present a clinical challenge due to inconsistent classification and uncertainty regarding their development and genetic potential. This scoping review aims to synthesise the existing evidence, identify gaps in the literature and propose a committee opinion on 2.1PN zygotes, including a working provisional definition, to guide clinical practice and future studies. A PubMed search for studies reporting 2.1PN zygotes and their developmental and clinical outcomes was conducted in May 2025. This review shows conflicting evidence regarding blastulation rates between 2.1PN and 2PN zygotes, and findings on preimplantation genetic testing and live birth rates remain inconclusive due to limited study numbers and sample sizes. Regardless, 2.1PN zygotes should be distinguished from classic 3PN zygotes, cultured to the blastocyst stage and genetically assessed if available. Based on current evidence and expert consensus, we propose a provisional working definition of the 2.1PN zygote to support standardised classification. Current evidence suggests that 2.1PN zygotes can be viable and warrant differentiation from 3PN zygotes. Future research should clarify the mechanisms underlying 2.1PN formation, determine neonatal and longer-term health outcomes following 2.1PN-derived embryo transfer and validate findings in larger cohorts.